{"id":"https://openalex.org/W2605501248","doi":"https://doi.org/10.1158/1538-7445.tummet15-b47","title":"Abstract B47: Drug-induced EMT is fundamentally distinct from pathologic EMT","display_name":"Abstract B47: Drug-induced EMT is fundamentally distinct from pathologic EMT","publication_year":2016,"publication_date":"2016-04-01","ids":{"openalex":"https://openalex.org/W2605501248","doi":"https://doi.org/10.1158/1538-7445.tummet15-b47","mag":"2605501248"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.tummet15-b47","doi":"https://doi.org/10.1158/1538-7445.tummet15-b47","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.tummet15-b47","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077630599","display_name":"Saeed Salehin Akhand","orcid":"https://orcid.org/0000-0002-4767-4761","observed_orcids":["https://orcid.org/0000-0002-4767-4761"]},"institutions":[{"id":"https://openalex.org/I219193219","display_name":"Purdue University West Lafayette","ror":"https://ror.org/02dqehb95","country_code":"US","type":"education","lineage":["https://openalex.org/I219193219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Saeed Salehin Akhand","raw_affiliation_strings":["Purdue University, West Lafayette, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue University, West Lafayette, IN","institution_ids":["https://openalex.org/I219193219"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090843213","display_name":"Michael K. Wendt","orcid":"https://orcid.org/0000-0002-3665-7413","observed_orcids":["https://orcid.org/0000-0002-3665-7413"]},"institutions":[{"id":"https://openalex.org/I219193219","display_name":"Purdue University West Lafayette","ror":"https://ror.org/02dqehb95","country_code":"US","type":"education","lineage":["https://openalex.org/I219193219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Wendt","raw_affiliation_strings":["Purdue University, West Lafayette, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue University, West Lafayette, IN","institution_ids":["https://openalex.org/I219193219"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I219193219"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"76","issue":"7_Supplement","first_page":"B47","last_page":"B47"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lapatinib-resistance","display_name":"lapatinib resistance","score":0.8849999904632568},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8109999895095825},{"id":"https://openalex.org/keywords/fgfr1","display_name":"FGFR1","score":0.9049999713897705},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.7210000157356262},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.984000027179718},{"id":"https://openalex.org/keywords/cancer-stem-cells","display_name":"cancer stem cells","score":0.7300000190734863},{"id":"https://openalex.org/keywords/cd44-cd24","display_name":"CD44/CD24","score":0.9139999747276306},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.8209999799728394},{"id":"https://openalex.org/keywords/fgfr-inhibitors","display_name":"FGFR inhibitors","score":0.5}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9459190964698792},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.705467700958252},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6199679374694824},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.5138504505157471},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5038544535636902},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.4856220781803131},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.4488074779510498},{"id":"https://openalex.org/C2779251935","wikidata":"https://www.wikidata.org/wiki/Q5385089","display_name":"ErbB","level":3,"score":0.4237782061100006},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4108968675136566},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34166979789733887},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3406860828399658},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.2789514362812042},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.1719585359096527},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.16359388828277588},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.12745746970176697},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.11656621098518372},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.07617676258087158}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.tummet15-b47","doi":"https://doi.org/10.1158/1538-7445.tummet15-b47","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.tummet15-b47","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2602264242","https://openalex.org/W2546654144","https://openalex.org/W3130249359","https://openalex.org/W2741057017","https://openalex.org/W2474565052","https://openalex.org/W2066516593","https://openalex.org/W2075846415","https://openalex.org/W4300854076","https://openalex.org/W2086224272","https://openalex.org/W2275827194"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Receptor":[2],"tyrosine":[3,33],"kinase":[4,34,176,211],"ErbB2":[5],"(Her2)":[6],"is":[7,376],"overexpressed":[8],"in":[9,43,100,220,275,290,304,351,354],"an":[10,182],"estimated":[11],"25%":[12],"of":[13,21,26,47,80,112,155,163,194,229,242,325,347,385],"the":[14,30,45,77,109,119,161,221,243,305,322,386],"breast":[15,49],"cancer":[16,50,56,244,296],"patients.":[17],"A":[18],"therapeutic":[19],"regime":[20],"Her2":[22,87,157],"targeted":[23],"therapies,":[24],"consists":[25],"Trastuzumab":[27,179],"followed":[28],"by":[29,255,362],"dual":[31],"EGFR/Her2":[32],"inhibitor,":[35,177],"Lapatinib.":[36,83,230],"These":[37],"therapies":[38],"continue":[39],"to":[40,61,75,93,201,207,215,250,273,288,311,330,343,356],"show":[41,205],"success":[42],"blocking":[44],"progression":[46,297],"this":[48,71],"subtype.":[51],"Of":[52],"clinical":[53],"concern,":[54],"however,":[55],"cells":[57,92,104,165,197,223,270,285,363],"eventually":[58],"develop":[59],"pathways":[60],"evade":[62],"Lapatinib-mediated":[63],"tumor":[64,337],"inhibition":[65,217],"and":[66,133,153,178,209,327],"acquire":[67],"drug":[68,185],"resistance.":[69],"In":[70],"study,":[72],"we":[73,262,300,319],"sought":[74],"understand":[76],"molecular":[78],"mechanism":[79],"resistance":[81,214],"towards":[82],"Methods:":[84],"We":[85,117,159,187],"used":[86],"overexpressing":[88],"human":[89],"mammary":[90],"epithelial":[91],"generate":[94],"Lapatinib":[95,113],"resistant":[96,200],"cell":[97,121,124,131,141,246],"lines":[98,142],"(LapR)":[99],"vitro.":[101],"The":[102],"LapR":[103,140,164,196,222,269,284,306,326],"acquired":[105],"growth":[106,257],"persistence":[107,353],"within":[108],"continued":[110],"presence":[111],"for":[114,224,335],"four":[115],"weeks.":[116],"analyzed":[118],"resultant":[120],"populations":[122],"via":[123],"viability":[125,162],"assays,":[126],"immunoblotting,":[127],"flow":[128],"cytometry,":[129],"3D":[130,278],"culture":[132],"Nano-string":[134,294],"gene":[135],"expression":[136,323],"analysis.":[137],"Results:":[138],"Generated":[139],"showed":[143],"robust":[144],"epithelial-mesenchymal":[145],"transition":[146],"(EMT)":[147],"phenotypes":[148],"that":[149,264],"included":[150],"upregulated":[151],"FGFR1":[152],"preservation":[154],"their":[156,266],"expression.":[158],"tested":[160],"using":[166,293],"dose":[167],"response":[168,355],"assays":[169],"with":[170,236],"Afatinib,":[171],"a":[172,237,251,276,312],"second-generation":[173],"covalent":[174,192],"ErbB":[175,216],"emtansine":[180],"(T-DM1),":[181],"anti-Her2":[183],"antibody":[184],"conjugate.":[186],"also":[188],"utilized":[189,361],"recently":[190],"developed":[191],"inhibitors":[193],"FGFR.":[195],"were":[198,271,286],"highly":[199],"Afatinib":[202],"but":[203],"did":[204],"sensitivity":[206],"T-DM1":[208],"FGFR":[210],"inhibition.":[212],"Importantly,":[213],"was":[218,234],"maintained":[219,238],"several":[225],"weeks":[226],"following":[227],"removal":[228],"This":[231],"stable":[232],"phenotype":[233,308],"consistent":[235],"yet":[239],"distinct":[240,378],"regulation":[241],"stem":[245],"markers":[247],"(CD44/CD24)":[248],"compared":[249,310],"transient":[252],"EMT":[253,307,329,348,375],"induced":[254,314],"transforming":[256],"factor":[258],"\u03b2":[259],"(TGF-\u03b2).":[260],"Strikingly,":[261],"observed":[263],"unlike":[265,281],"parental":[267],"counterparts":[268],"unable":[272,287],"grow":[274],"compliant":[277],"matrix.":[279],"Furthermore,":[280],"TGF-\u03b2-treated":[282],"cells,":[283],"metastasize":[289],"vivo.":[291],"By":[292],"pan":[295],"panel":[298],"analysis,":[299],"characterized":[301],"key":[302,332],"differences":[303],"as":[309],"TGF-\u03b2":[313],"EMT.":[315,381],"Future":[316],"Directions:":[317],"Currently,":[318],"are":[320,349],"analyzing":[321],"data":[324],"TGF-\u03b2-induced":[328],"identify":[331],"targets":[333],"required":[334],"EMT-induced":[336],"progression.":[338,366],"Overall,":[339],"our":[340],"studies":[341],"seek":[342],"define":[344],"what":[345],"aspects":[346],"involved":[350],"cellular":[352],"anti-cancer":[357],"drugs":[358],"versus":[359],"those":[360],"during":[364],"metastatic":[365],"Citation":[367],"Format:":[368],"Saeed":[369],"Salehin":[370],"Akhand,":[371],"Michael":[372],"Wendt.":[373],"Drug-induced":[374],"fundamentally":[377],"from":[379],"pathologic":[380],"[abstract].":[382],"In:":[383],"Proceedings":[384],"AACR":[387],"Special":[388],"Conference":[389],"on":[390],"Tumor":[391],"Metastasis;":[392],"2015":[393],"Nov":[394],"30-Dec":[395],"3;":[396],"Austin,":[397],"TX.":[398],"Philadelphia":[399],"(PA):":[400],"AACR;":[401],"Cancer":[402],"Res":[403],"2016;76(7":[404],"Suppl):Abstract":[405],"nr":[406],"B47.":[407]},"counts_by_year":[],"updated_date":"2026-07-14T23:27:15.235271","created_date":"2017-04-28T00:00:00"}